Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 3Hand-Foot Syndrome 2Drug-Related Side Effects and Adverse Reactions 2Breast Neoplasms, Male 2Rectal Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Cancer Related Fatigue 1

Interventions

exemestane 4Tamoxifen 3Paclitaxel 3Letrozole 3Goserelin 3Cyclophosphamide 3pegfilgrastim 2Radiotherapy 2Pyridoxine 2Leuprolide 2Fluorouracil 2Epirubicin 2Capecitabine 2Bevacizumab 2Anastrozole 2trastuzumab biosimilar HLX02 1ribociclib 1elacestrant 1Zoledronic Acid 1Trastuzumab 1Taxes 1Radiosurgery 1Prochlorperazine 1Palonosetron 1PF-05280014 1Ontruzant 1Ogivri 1Neoadjuvant Therapy 1Mometasone Furoate 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms, Male × Pyridoxine × Clear all
NCT00559858 2013-08-02

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
270 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Breast Neoplasms, Male, Hand-Foot Syndrome

NCT00245050 2011-12-30

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Case Comprehensive Cancer Center

Phase 3 Completed
34 enrolled 9 charts
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡